Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
May 23, 2023: Eisai Delivers new data and highlights continued progress of oncology portfolio and pipeline at ASCO 2023
May 15, 2023: Merck to present extensive new research demonstrating significant progress in the treatment of certain earlier stage cancers and in advancing broad oncology pipeline at 2023 ASCO Annual Meeting
May 15, 2023: Eisai Co announces consolidated financial report for fiscal 2022
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Eisai Co Ltd (Eisai) is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China, and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.Eisai Co Ltd Key Recent Developments
May 25, 2023: Eisai’s initiatives for developing new medicines for neglected tropical diseases and malaria and commitment for funding to the 3rd phase of global health innovative technology fund activitiesMay 23, 2023: Eisai Delivers new data and highlights continued progress of oncology portfolio and pipeline at ASCO 2023
May 15, 2023: Merck to present extensive new research demonstrating significant progress in the treatment of certain earlier stage cancers and in advancing broad oncology pipeline at 2023 ASCO Annual Meeting
May 15, 2023: Eisai Co announces consolidated financial report for fiscal 2022
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Astellas Pharma Inc
- Mochida Pharmaceutical Co Ltd
- Kaken Pharmaceutical Co Ltd
- Cassava Sciences Inc
- Chugai Pharmaceutical Co Ltd
- Takeda Pharmaceutical Co Ltd
- Ono Pharmaceutical Co Ltd
- Nippon Kayaku Co Ltd
- Daiichi Sankyo Inc
- Cassava Sciences Inc
- Chugai Pharmaceutical Co Ltd
- Daiichi Sankyo Inc
- Ono Pharmaceutical Co Ltd
- Nippon Kayaku Co Ltd
- Astellas Pharma Inc
- Mochida Pharmaceutical Co Ltd
- Kaken Pharmaceutical Co Ltd